Back to Results
First PageMeta Content
Rivaroxaban / Thiophenes / Heparins / Sanofi / Enoxaparin sodium / Deep vein thrombosis / Direct Xa inhibitor / Pulmonary embolism / Knee replacement / Anticoagulants / Medicine / Morpholines


Rivaroxaban Superior to U.S.-Approved Dosing Regimen for Enoxaparin in Reducing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial First Novel, Oral Anticoagulant to Consistently Demonstra
Add to Reading List

Open Document

File Size: 12,79 KB

Share Result on Facebook

City

NICE / Raritan / /

Company

BUSINESS WIRE / Bayer HealthCare AG / Scios Inc. / Johnson & Johnson Pharmaceutical Research & Development L.L.C. / Ortho-McNeil Inc. / J&JPRD / /

Continent

Asia / Europe / /

Country

France / United States / Canada / China / /

/

Event

FDA Phase / /

Facility

McMaster University / /

IndustryTerm

producer / health care products / /

MedicalCondition

non-fatal pulmonary embolism / Venous Blood Clots / proximal deep vein thrombosis / total venous thromboembolism / deep vein thrombosis / blood clot / Venous Thromboembolism / dangerous blood clots / pulmonary embolism / /

MedicalTreatment

Total Knee Replacement Surgery / total hip replacement / knee replacement / hip surgery / Orthopedic surgery / hip replacement surgery / hip replacement / knee replacement surgery / hip and knee replacement surgeries / knee surgery / surgery / total knee replacement / /

Organization

European Agency for the Evaluation of Medicinal Products / McMaster University / Food and Drug Administration / FDA / European Federation of National Associations of Orthopaedics & Traumatology / European Union / /

Person

A.G.G. Turpie / Louise Mehrotra / Lesley Fishman / Steven Cooper / Ernie Knewitz / /

/

Position

broadly based producer / Major / Principal Investigator for the RECORD program / Professor of Medicine / /

Product

Oral Anticoagulant / RECORD4 / /

ProvinceOrState

New Jersey / /

Technology

drug discovery / drug development / /

URL

http /

SocialTag